Actual Nurtec ODT Patient. Individual results may vary.
CGRP: calcitonin gene-related peptide
No titration needed1
Can be taken up to
once daily as needed.
No water necessary.1,*
Can be co‑administered
with oral contraceptives
Studied in patients
in people with stable
or risk factors.1,6
*The safety of treating more than 15 migraines in a 30-day period has not been established.1
How to Take
Instruct patients to only
remove Nurtec ODT
from the blister pack
immediately before use1
No titration needed1
Patients can place
Nurtec ODT on or under
their tongue and it
In clinical trials, some
pain relief and returned
to normal function in
just 60 minutes with
Nurtec ODT has
a Tmax of 1.5 hours1
In a multi-center, double-blind, randomized, placebo-controlled study of 1351 patients (Nurtec ODT 75 mg, n=669; placebo, n=682), the co-primary endpoints were freedom from pain and the absence of the most bothersome symptom (MBS) 2 hours post dose.1
*37% (n=246/669) patients experienced pain relief vs 31% (n=213/682) on placebo (P<.05).2
22% (n=149/669) patients experienced return to normal function vs 16% (n=108/682) on placebo (P=.0025).2,8
How to prescribe Nurtec ODT1
Prescribing Nurtec ODT 8-packs1
Each 8-pack of Nurtec ODT is meant to cover 8 migraine
attacks, as needed up to once daily.
Prescription: "Once daily PRN for migraine"
The safety of treating more than 15 migraines in a
30-day period has not been established.
Additional prescribing considerations1:
Packaging: Nurtec ODT comes in 8-tablet packs
Once daily PRN: Take one 75 mg orally disintegrating tablet (ODT), as needed, for migraine
24 hour max: one 75 mg ODT
30 day max: The safety of treating more than 15 migraines in a 30 day period has not been established
Getting started with Nurtec ODT
Questions? We're here to help: Call us at 1‑833‑4NURTEC (M-F from 8 am - 8 pm ET)
References: 1. Nurtec ODT. Package insert. Biohaven Pharmaceuticals Inc. 2. Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394(10200):737-745. doi: 10.1016/S0140-6736(19)31606-X. 3. Hutchinson S, Schim J, Lipton RB, et al. Rimegepant is safe and tolerable for the acute treatment of migraine in patients using preventive migraine medications: Results from a long-term open-label safety study (study 201). Poster presented at: Virtual Annual Scientific Meeting of the American Headache Society; June 13, 2020. 4. Baskin SM, Buse DC, Jensen CM, et al. Rimegepant 75 mg is safe and well tolerated for the acute treatment of migraine in adults using selective serotonin reuptake inhibitors and other antidepressants: Results from a long-term open-label safety study (study 201). Poster presented at: Virtual Annual Scientific Meeting of the American Headache Society; June 13, 2020. 5. Berman G, Kudrow D, Halverson P, et al. Oral rimegepant 75 mg is well tolerated when used concomitantly with injectable anti-CGRP monoclonal antibodies: Results from a multicenter, long-term, open-label safety study. Poster presented at: Virtual Annual Scientific Meeting of the American Headache Society; June 13, 2020. 6. Data on File. RIM130. Biohaven Pharmaceuticals Inc. 7. Abay FB, Ugurlu T. Orally Disintegrating Tablets: A Short Review. J Pharm Drug Devel. 2015;3(3):303-311. doi: 10.15744/2348-9782.3.303. 8. Lipton RB, Coric V, Stock EG, et al. Efficacy, safety, and tolerability of rimegepant 75 mg orally dissolving tablet for the acute treatment of migraine: a phase 3, double-blind, randomized, placebo-controlled trial (study 303). Abstract presented at: 61st Annual Scientific Meeting of the American Headache Society; Philadelphia, PA. Session IOR05; July 11, 2019.
< Previous Page
Next Page >
Savings & Support
Important Safety Information
Contraindications: Hypersensitivity to Nurtec ODT or any of its components.
Warnings and Precautions: If a serious hypersensitivity reaction occurs, discontinue Nurtec ODT and initiate appropriate therapy. Serious hypersensitivity reactions have included dyspnea and rash, and can occur days after administration.
Adverse Reactions: The most common adverse reaction was nausea (2% in patients who received Nurtec ODT compared to 0.4% in patients who received placebo). Hypersensitivity, including dyspnea and rash, occurred in less than 1% of patients treated with Nurtec ODT.
Drug Interactions: Avoid concomitant administration of Nurtec ODT with strong inhibitors of CYP3A4, strong or moderate inducers of CYP3A or inhibitors of P‑gp or BCRP. Avoid another dose of Nurtec ODT within 48 hours when it is administered with moderate inhibitors of CYP3A4.
Use in Specific Populations: Pregnant/breast feeding: It is not known if Nurtec ODT can harm an unborn baby or if it passes into breast milk. Hepatic impairment: Avoid use of Nurtec ODT in persons with severe hepatic impairment. Renal impairment: Avoid use in patients with end-stage renal disease.
Nurtec ODT is indicated for the acute treatment of migraine with or without aura in adults.
Limitations of Use
Nurtec ODT is not indicated for the preventive treatment of migraine.
Please click here for full Prescribing Information.